🇺🇸 FDA

Company profile · Sponsor

Rein

Rein Therapeutics

RNTX · NYSE pharma AUSTIN, TX, USA
Pipeline
11
Drugs
0
Patents
8

Quick answer

Rein (RNTX) is a pharma company. headquartered in AUSTIN, TX, USA. listed on NYSE. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker RNTX
Exchange NYSE
Company type pharma
Headquarters AUSTIN, TX, USA
SEC CIK 0001420565

Pipeline (11)

Search pipeline →

  1. Identical to the Test product, XGEVA 120 mg solution for injection

    Rein

    Prevention of breast cancer in women with a BRCA1 germline mutation

    phase 3 small molecule active

    1 trial

  2. Nivolumab

    Rein

    Metastatic Kidney Cancer

    phase 3 small molecule active

    1 trial

  3. TAMOXIFEN, LETROZOLE, ANASTROZOLE, FULVESTRANT, LEUPRORELIN, OXYBUTYNIN, GOSERELIN, VENLAFAXINE, LEUPRORELIN, GOSERELIN, EXEMESTANE, VENLAFAXINE

    Rein

    Breast cancer

    phase 3 small molecule active

    1 trial

  4. LTI-01

    Rein

    Pleural Effusion

    phase 2 small molecule completed

    1 trial

  5. LTI-03

    Rein

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  6. LTI-03, The placebo is InhaLac® 500 (micronized lactose monohyrdate).

    Rein

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  7. Lynparza 100 mg film-coated tablets, CYCLOPHOSPHAMIDE, Lynparza 150 mg film-coated tablets, DOCETAXEL, DOXORUBICIN, CARBOPLATIN, EPIRUBICIN

    Rein

    Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)

    phase 2 small molecule active

    1 trial

  8. ORSERDU 86 mg film-coated tablets, LETROZOLE , -, ORSERDU 345 mg film-coated tablets, Kisqali 200 mg film-coated tablets, EXEMESTANE , ANASTROZOLE

    Rein

    endocrine-responsive HER2-negative early breast cancer

    phase 2 small molecule active

    1 trial

  9. Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)

    Rein

    Idiopathic Pulmonary Fibrosis

    phase 1 small molecule completed

    1 trial

  10. LTI-03

    Rein

    Idiopathic Pulmonary Fibrosis

    phase 1 small molecule completed

    1 trial

  11. SODIUM CHLORIDE, Ondansetron Morningside 4 mg orodispergeerbare tabletten, Ondansetron 2 mg/ml Solution for Injection, Ketanest® S 5 mg/ml - Ampullen

    Rein

    Endometriosis

    approved small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12390512

    Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11033623

    Magnetic stem cell therapy for lesions

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10472381

    Sialic acid derivatives

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10265396

    Magnetic extracellular matrix

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9539228

    Composition containing lysine as a nutritional supplement or treatment in the case of herpes

    Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8309071

    Foamy viral envelope genes

    Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8293803

    Retinoid compounds and their use

    Expires Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8268792

    Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases

    Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Rein?

Rein (RNTX) is a pharma company. headquartered in AUSTIN, TX, USA. listed on NYSE. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Rein sponsor?

We track 11 ClinicalTrials.gov-linked programs for Rein, including Identical to the Test product, XGEVA 120 mg solution for injection and 10 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Rein company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.